Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Apellis Pharmaceuticals, Inc. (APLS) had Revenue of $781.37M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$781.37M
Net Income	$-197.88M
Cost of Goods Sold	$117.72M
Gross Profit	$663.64M
Operating Expenses	$946.35M
Operating Income	$-164.98M
Non-Operating Income/Expense	$-31.74M
Pre-Tax Income	$-196.72M
Normalized Pre-Tax Income	$-196.72M
Income after Taxes	$-197.88M
Income from Continuous Operations	$-197.88M
Consolidated Net Income/Loss	$-197.88M
Normalized Income after Taxes	$-197.88M
EBIT	$-164.98M
EBITDA	$-152.69M
Weighted-Average Shares Outstanding (Basic)	123.91M
Weighted-Average Shares Outstanding (Diluted)	123.91M
Earnings per Share (EPS) (Basic)	$-1.60
Earnings per Share (EPS) (Diluted)	$-1.60
Balance Sheet Financials
Current Assets	$788.95M
Property, Plant, and Equipment	$2.95M
Long-Term Assets	$96.10M
Total Assets	$885.05M
Current Liabilities	$185.51M
Long-Term Debt	$452.83M
Long-Term Liabilities	$471.00M
Total Liabilities	$656.51M
Common Equity	$228.54M
Tangible Shareholders Equity	$228.54M
Shareholders Equity	$228.54M
Common Shares Outstanding	124.50M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-87.87M
Cash Flow from Investing Activities	$-0.40M
Cash Flow from Financial Activities	$149.24M
Beginning Cash	$352.30M
End Cash	$412.61M
Increase/Decrease in Cash	$60.31M
Stock-Based Compensation	$114.13M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.25
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.66
Debt to Equity Ratio	1.98
Gross Margin	84.93%
Operating Margin	-21.11%
EBIT Margin	-21.11%
EBITDA Margin	-19.54%
Pre-Tax Profit Margin	-25.18%
Profit Margin	-25.32%
Free Cash Flow	$-88.27M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.88
Inventory Turnover	1.45
Receiveable Turnover	2.95
Days Sales in Receivables	123.75
Return on Equity	-86.58%
Return on Tangible Equity	-86.58%
Return on Assets	-22.36%
Return on Investments	-29.04%
Book Value Per Share	$1.84
Free Cash Flow per Share	$-0.71
Operating Cash Flow per Share	$-0.71

Data from Zacks Investment Research, Inc.